Skip to main content
Fig. 2 | BMC Gastroenterology

Fig. 2

From: Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

Fig. 2

Quality assessment results for studies contributing data to the analyses for A Crohn’s disease and B ulcerative colitis. Panel A: Risk of bias determined based on assessment of the following study publications: SONIC, NOR-SWITCH, GEMINI 2, GEMINI 3, CT-P13 SC trial, and PLANET CD. Abbreviation: SC, subcutaneous. Panel B: Risk of bias determined based on assessment of the following study publications: GEMINI 1, NOR- SWITCH, ACT 1, ACT 2, VISIBLE 1, VARSITY, and CT-P13 SC trial. Abbreviation: SC, subcutaneous

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us